William Blair initiated coverage of Cardinal Health with a rating of Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/28/2026 | Outperform | William Blair | |
| 1/9/2026 | Neutral → Buy | Citigroup | |
| 12/9/2025 | $243.00 | Overweight | Barclays |
| 6/3/2025 | $179.00 | Equal Weight → Overweight | Wells Fargo |
| 2/5/2025 | $140.00 → $150.00 | Hold → Buy | Jefferies |
| 1/8/2025 | $130.00 → $144.00 | Hold → Buy | TD Cowen |
| 1/7/2025 | $140.00 | In-line → Outperform | Evercore ISI |
| 1/6/2025 | $132.00 → $145.00 | Neutral → Buy | BofA Securities |
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
William Blair initiated coverage of Cardinal Health with a rating of Outperform
Citigroup upgraded Cardinal Health from Neutral to Buy
Barclays initiated coverage of Cardinal Health with a rating of Overweight and set a new price target of $243.00
DUBLIN, Ohio, March 23, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced that its Board of Directors has appointed Patricia A. Hemingway Hall to succeed Gregory B. Kenny as Chair of the Board following Mr. Kenny's retirement, effective immediately. Mr. Kenny has served on the Board since 2007 and as Chairman since 2018. During his tenure on the Board, Mr. Kenny supported the Company through periods of significant transformation, including strategic portfolio evolution and operational improvement initiatives."On behalf of the Board and our management team, we are d
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv
Carlisle Companies Incorporated (NYSE:CSL) today announced the appointment of Christopher B. Gaskill as Vice President & General Counsel for the Company. In conjunction with this appointment, Scott C. Selbach will transition to a new role as Executive Vice President, Government Relations for the Company. Mr. Selbach will also remain Secretary of the Company. Both Mr. Gaskill and Mr. Selbach will report to Chris Koch, Carlisle's Chair, President & Chief Executive Officer. Prior to joining Carlisle, Mr. Gaskill served as Executive Vice President, Chief Legal Officer, and Secretary at Summit Materials, Inc. (NYSE:SUM), where he was responsible for the company's global legal functions and ensu
DUBLIN, Ohio, May 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved an increase to its quarterly dividend to $0.5158 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2026 to shareholders of record at the close of business on July 1, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an opera
Revenue increased 11% to $60.9 billionGAAP1 operating earnings decreased 30% to $509 million; GAAP diluted EPS decreased 20% to $1.69Non-GAAP operating earnings increased 18% to $956 million; non-GAAP diluted EPS increased 35% to $3.17Cardinal Health raises and narrows fiscal year 2026 non-GAAP EPS guidance2 to $10.70 to $10.80Cardinal Health reduces debt and completes additional $250 million share repurchase, bringing FY26 repurchase total to $1.0 billionDUBLIN, Ohio, April 30, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported third quarter fiscal year 2026 revenues of $60.9 billion, an increase of 11% from the third quarter of fiscal year 2025.Third quarter GAAP operating earn
DUBLIN, Ohio, Feb. 12, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on April 15, 2026 to shareholders of record at the close of business on April 1, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuc
DUBLIN, Ohio, May 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved an increase to its quarterly dividend to $0.5158 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2026 to shareholders of record at the close of business on July 1, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an opera
Revenue increased 11% to $60.9 billionGAAP1 operating earnings decreased 30% to $509 million; GAAP diluted EPS decreased 20% to $1.69Non-GAAP operating earnings increased 18% to $956 million; non-GAAP diluted EPS increased 35% to $3.17Cardinal Health raises and narrows fiscal year 2026 non-GAAP EPS guidance2 to $10.70 to $10.80Cardinal Health reduces debt and completes additional $250 million share repurchase, bringing FY26 repurchase total to $1.0 billionDUBLIN, Ohio, April 30, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported third quarter fiscal year 2026 revenues of $60.9 billion, an increase of 11% from the third quarter of fiscal year 2025.Third quarter GAAP operating earn
Research confirms advanced therapies are moving beyond inpatient hospitals, with providers increasingly supporting partnerships that bring life-changing treatments closer to patients' homes.DUBLIN, Ohio, April 14, 2026 /PRNewswire/ -- Today, Cardinal Health (NYSE:CAH) released its 2026 Advanced Therapies Report: Perspectives on Community Expansion, offering new insights into how the expanding advanced therapy pipeline is reshaping sites of care. Advanced therapies are innovative gene-, cell- and tissue-based treatments that target the root cause of disease by repairing, replacing or regenerating damaged cells, offering long-term benefits for many conditions. As more therapies shift to outpat
SD - CARDINAL HEALTH INC (0000721371) (Filer)
10-Q - CARDINAL HEALTH INC (0000721371) (Filer)
8-K - CARDINAL HEALTH INC (0000721371) (Filer)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)
SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)